Search

Displaying results 2211 - 2220 of 8517 in total
  1. Drug

    Chlorambucil

    go.drugbank.com/drugs/DB00291
    ApprovedInvestigational

    Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed) … A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases.

    Synonyms: 4-(p-bis(beta-chloroethyl)aminophenyl)butyric acid, 4-(p-bis(β-chloroethyl)aminophenyl)butyric acid
  2. Drug

    Paritaprevir

    go.drugbank.com/drugs/DB09297
    ApprovedInvestigational

    Paritaprevir is also available as a fixed-dose combination product with [DB09296] and [DB00503] as the FDA- and Health Canada-approved product Technivie. … Paritaprevir first came on the market as a fixed-dose combination product with [DB09296], [DB09183], and [DB00503] as the FDA-approved product Viekira Pak.

  3. Drug

    Cytarabine

    go.drugbank.com/drugs/DB00987
    ApprovedInvestigational

    It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

  4. Drug

    Albinterferon Alfa-2B

    go.drugbank.com/drugs/DB05396
    Investigational

    The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C. … Human Genome Sciences is developing Albuferon as a potential treatment for chronic hepatitis C.

  5. Drug

    Garadacimab

    go.drugbank.com/drugs/DB15629
    Approved

    [L53283] It was developed by CSL Behring for use as a prophylactic agent in patients with hereditary angioedema (HAE), a rare autosomal dominant disorder that results in acute episodes of angioedema. … [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age.

  6. Drug

    Manganese gluconate

    go.drugbank.com/drugs/DB11141
    Approved

    Manganese gluconate is a direct ingredient in food substances as a nutrient supplement. In pharmaceutical preparations it is used as a [DB06757] supplement.

  7. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved

  8. Drug

    NGD-4715

    go.drugbank.com/drugs/DB06027
    Experimental

    NGD-4715 functions as a melanin-concentrating hormone receptor 1 antagonist.

  9. Drug

    Bromelains

    go.drugbank.com/drugs/DB13281
    ApprovedInvestigational

    It works by selectively inhibiting the biosynthesis of proinflammatory prostaglandins [A27197] and also has analgesic properties, as well as anticancerous and pro-apoptotic effects. … It is considered as a safe food supplement.

  10. Drug

    Fosaprepitant

    go.drugbank.com/drugs/DB06717
    ApprovedInvestigational

    Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.